TUMADOR

Development of very promising humanized therapeutic mAbs efficiently neutralizing a novel immunosuppressive pathway involved in a wide range of cancers

Coordinatore	CENTRE ANTICANCEREUX LEON BERARD    more  Organization address address: RUE LAENNEC 28 city: LYON postcode: 69373 contact info Titolo: Dr. Nome: Marina Cognome: Rousseau Email: send email Telefono: +33 04 78 78 28 43
Nazionalità Coordinatore	France [FR]
Totale costo	7˙748˙224 €
EC contributo	5˙978˙890 €
Programma	FP7-HEALTH Specific Programme "Cooperation": Health
Code Call	FP7-HEALTH-2013-INNOVATION-1
Funding Scheme	CP-FP
Anno di inizio	2013
Periodo (anno-mese-giorno)	2013-09-01   -   2017-08-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	CENTRE ANTICANCEREUX LEON BERARD  Organization address address: RUE LAENNEC 28 city: LYON postcode: 69373 contact info Titolo: Dr. Nome: Marina Cognome: Rousseau Email: send email Telefono: +33 04 78 78 28 43	FR (LYON)	coordinator	1˙595˙920.00
2	INNATE PHARMA  Organization address address: AVENUE DE LUMINY 117 city: MARSEILLE postcode: 13009 contact info Titolo: Mr. Nome: Nicolas Cognome: Dams Email: send email Telefono: +33 4 30 30 30 53	FR (MARSEILLE)	participant	1˙799˙304.00
3	GENEWAKE GMBH  Organization address address: Floriansbogen 2-4 city: NEURIED postcode: 82061 contact info Titolo: Dr. Nome: Robert Cognome: Loewe Email: send email Telefono: +49 08974419166 Fax: +49 08974419164	DE (NEURIED)	participant	748˙180.00
4	TURUN YLIOPISTO  Organization address address: YLIOPISTONMAKI city: TURUN YLIOPISTO postcode: 20014 contact info Titolo: Dr. Nome: Mari Cognome: Riipinen Email: send email Telefono: +358 2 3336054 Fax: +358 2 3336446	FI (TURUN YLIOPISTO)	participant	599˙960.00
5	THE UNIVERSITY OF TEXAS SYSTEM  Organization address address: COLORADO STREET 601 city: AUSTIN postcode: 78701 2982 contact info Titolo: Dr. Nome: Tyler Cognome: Curiel Email: send email Telefono: +1 2105624083	US (AUSTIN)	participant	466˙841.00
6	UNIVERSITE DE LAUSANNE  Organization address city: LAUSANNE postcode: 1015 contact info Titolo: Prof. Nome: Pedro Cognome: Romero Email: send email Telefono: +41 213140198 Fax: +41 213147477	CH (LAUSANNE)	participant	448˙425.00
7	ALMA CONSULTING GROUP SAS  Organization address address: Domaine des Bois d'Houlbec city: HOULBEC COCHEREL postcode: 27120 contact info Titolo: Ms. Nome: Fabienne Cognome: Brutin Email: send email Telefono: +33 4 72 35 88 26	FR (HOULBEC COCHEREL)	participant	205˙860.00
8	POLYGENE AG	CH	participant	114˙400.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Studies have demonstrated the importance of CD73 in the spread of cancer. Overexpressed in numerous cancer types, this enzyme leads to the production of high amounts of extracellular Adenosine, creating an immunosuppressive microenvironment, and contributing to tumor proliferation and dissemination. Neutralizing its activity represents a highly potent and innovative therapy. Following on the recent success of mAbs targeting immune checkpoint (PD1, CTLA4), TumAdoR aims to discover, characterize and produce humanized anti-hCD73 mAbs that will be assessed for their efficacy and safety in relevant mouse preclinical tumor models. It will result in the development of anti-CD73 drug candidates that will strengthen the immune system, stop cancer cell progression and prevent relapse through restoration of immune memory. TumAdoR aims at paving the way to first-in-human clinical trials of potent mAb candidates, and validating a new cancer immunotherapy, suitable for a wide range of cancers.

More precisely, TumAdoR will: •Reinforce knowledge about CD73 role as an immune checkpoint target •Correlate CD73 expression with clinical outcome and validate the tumor patients most likely to benefit from CD73 blockade •Discover and develop mAbs neutralizing hCD73 •Develop relevant preclinical tumor models to validate the in vivo efficacy and safety of anti-CD73 mAbs candidate(s) •Develop and standardize tools to assess CD73 expression, and monitor immune parameters in patients

TumAdoR addresses topic 1 by developing antibodies neutralizing CD73, and topic 3 by fighting against immune evasion in tumor host microenvironment. The high-level consortium including 3 SMEs possesses all the scientific and clinical expertises, industrial competences, biological and enzymatic assays, biological and clinical resources, and preclinical models to discover and produce mAbs, and investigate the functions of CD73, and the therapeutic impact of its neutralization.'